{"": [131, 2240, 0], "1. Introduction": [2241, 6990, 0], "2.1. Animals": [7017, 8326, 0], "2.2. SARS-CoV-2 and Cells": [8327, 9200, 0], "2.3.1. Intranasal Administration of Astodrimer Sodium 1% Nasal Spray Formulation": [9268, 10174, 0], "2.3.2. Intranasal and Intratracheal Administration of Astodrimer Sodium 1% Nasal Spray Formulation": [10175, 11376, 0], "2.3.3. Virucidal Intervention with Astodrimer Sodium 1% Nasal Spray Formulation": [11377, 12166, 0], "2.3. Antiviral and Virucidal Efficacy Studies Experimental Design": [9201, 12166, 1], "2.4. Determination of Endpoints": [12167, 15962, 0], "2.5. Statistical Analysis": [15963, 16602, 0], "2. Materials and Methods": [6991, 16602, 1], "3.1. Body Weight and Mortality": [16615, 16980, 0], "3.2. Time-Course of Viraemia": [16981, 18847, 0], "3.3. Viral Load\u2014Nasal Secretion": [18848, 20664, 0], "3.4. Viral Load\u2014Whole Tissue Homogenate": [20665, 22720, 0], "3.5. Pro-Inflammatory Cytokines and Chemokine Detection in Serum, Trachea and Lung Homogenates": [22721, 25518, 0], "3. Results": [16603, 25518, 1], "4. Discussion": [25519, 33050, 0], "5. Conclusions": [33051, 33772, 0]}